# Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer

> **NCT05136326** · PHASE2 · RECRUITING · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 21 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **RADIATION:** External-beam radiation
- **DRUG:** Capecitabine
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT05136326
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-01
- **Primary completion:** 2023-12
- **Final completion:** 2026-12
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2023-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05136326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05136326, "Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT05136326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*